Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 29.531
Filtrer
1.
BMC Pulm Med ; 24(1): 341, 2024 Jul 15.
Article de Anglais | MEDLINE | ID: mdl-39010041

RÉSUMÉ

Chronic obstructive pulmonary disease (COPD) has been associated with alterations in the brain cortical structure. Nonetheless, the causality between COPD and brain cortical structure has not been determined. In the present study, we used Mendelian randomization (MR) analysis to explore the causal effects of genetic predicated COPD on brain cortical structure, namely cortical surface area (SA) and cortical thickness (TH). Genetic association summary data for COPD were obtained from the FinnGen consortium (N = 358,369; Ncase = 20,066). PRISm summary genetic data were retrieved from a case-control GWAS conducted in the UK Biobank (N = 296,282). Lung function indices, including forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC, were extracted from a meta-analysis of the UK Biobank and SpiroMeta consortium (N = 400,102). Brain cortical structure data were obtained from the ENIGMA consortium (N = 51,665). Inverse-variance weighted (IVW) method was used as the primary analysis, and a series of sensitivity tests were exploited to evaluate the heterogeneity and pleiotropy of our results. The results identified potential causal effects of COPD on several brain cortical specifications, including pars orbitalis, cuneus and inferior parietal gyrus. Furthermore, genetic predicated lung function index (FEV1, FVC and FEV1/FVC), as well as PRISm, also has causal effects on brain cortical structure. According to our results, a total of 15 functional specifications were influenced by lung function index and PRISm. These findings contribute to understanding the causal effects of COPD and lung function to brain cortical structure.


Sujet(s)
Analyse de randomisation mendélienne , Broncho-pneumopathie chronique obstructive , Humains , Broncho-pneumopathie chronique obstructive/génétique , Broncho-pneumopathie chronique obstructive/physiopathologie , Volume expiratoire maximal par seconde , Capacité vitale , Étude d'association pangénomique , Cortex cérébral/imagerie diagnostique , Cortex cérébral/physiopathologie , Cortex cérébral/anatomopathologie , Mâle , Polymorphisme de nucléotide simple , Études cas-témoins , Poumon/physiopathologie
2.
Int J Chron Obstruct Pulmon Dis ; 19: 1623-1633, 2024.
Article de Anglais | MEDLINE | ID: mdl-39011121

RÉSUMÉ

Background: Chronic obstructive pulmonary disease (COPD) is a major public health problem that remains largely under-diagnosed, mainly due to the under-use of spirometry to establish the diagnosis. The aim of this study is to evaluate the effectiveness of the Moroccan Arabic dialect version of the COPD Assessment Test (CAT) in screening for COPD. Methods: This was a cross-sectional study carried out in primary care facilities in Morocco, involving participants aged 40 and over. The performance of CAT in detecting cases of COPD was measured with reference to the results of spirometry, considered to be the gold Standard. Results: A total of 477 participants were included in the study. The prevalence of COPD was 6.7%. Internal consistency of the Moroccan Arabic dialect version of the CAT was high, with a Cronbach's alpha of 0.89. The total score of the CAT and of each item was significantly higher in subjects with COPD than in those without (P=0.000). Significantly negative correlations were found between CAT total score and FEV1 (r = -0.33, p=0.000), CAT and FVC (r = -0.22, p=0.000), CAT and FEV1/FVC ratio (r = -0.22, p=0.000). The receiver operating characteristic curve showed an area under the curve of 0.93. A CAT score of 10 was the optimal cut-off value for COPD screening, with a sensitivity, specificity, positive predictive value, and negative predictive value of 78.1%, 93.9%, 48.1% and 98.4%, respectively. Conclusion: The results of the present study showed that the CAT could be used as a screening tool for COPD. The use of this tool by healthcare professionals in primary care settings will improve and promote early diagnosis of this chronic disease.


Sujet(s)
Poumon , Dépistage de masse , Valeur prédictive des tests , Broncho-pneumopathie chronique obstructive , Spirométrie , Humains , Broncho-pneumopathie chronique obstructive/diagnostic , Broncho-pneumopathie chronique obstructive/physiopathologie , Broncho-pneumopathie chronique obstructive/épidémiologie , Études transversales , Mâle , Adulte d'âge moyen , Femelle , Sujet âgé , Maroc/épidémiologie , Volume expiratoire maximal par seconde , Reproductibilité des résultats , Capacité vitale , Poumon/physiopathologie , Prévalence , Adulte , Dépistage de masse/méthodes , Enquêtes et questionnaires , Soins de santé primaires , Traduction
4.
Int J Chron Obstruct Pulmon Dis ; 19: 1547-1559, 2024.
Article de Anglais | MEDLINE | ID: mdl-38979101

RÉSUMÉ

Purpose: This study aimed to reveal the association between the osteoporosis self-assessment tool for Asians (OSTA) and airflow limitation (AL) in post-menopausal Japanese women. Participants and Methods: This cross-sectional study included 1580 participants undergoing a comprehensive health examination using spirometry and dual-energy X-ray absorptiometry. The OSTA was calculated by subtracting the age in years from the body weight (BW) in kilograms, and the result was multiplied by 0.2. The OSTA risk level was defined as low (>-1), moderate (-4 to -1), or high (<-4). AL was defined as forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) <0.7. The association between the OSTA and AL was assessed using logistic regression analysis. Results: The prevalence of AL was significantly higher in the high OSTA group (15.3%) than in the low OSTA group (3.1%) (p<0.001). In multiple linear regression analysis, the OSTA was independently associated with FEV1/FVC. In logistic regression models adjusted for smoking status, alcohol consumption, current use of medication for diabetes, hyperglycemia, rheumatoid arthritis, second-hand smoke, and ovary removal showed a significantly higher risk of AL (odds ratio: 5.48; 95% confidence interval: 2.90-10.37; p<0.001) in participants with OSTA high risk than in those with OSTA low risk. Conclusion: These results suggest that the OSTA high risk indicates reduced BMD at the femoral neck and presence of AL in Japanese post-menopausal women aged ≥45 years.


Sujet(s)
Absorptiométrie photonique , Asiatiques , Poumon , Post-ménopause , Spirométrie , Humains , Femelle , Études transversales , Adulte d'âge moyen , Japon/épidémiologie , Sujet âgé , Volume expiratoire maximal par seconde , Facteurs de risque , Capacité vitale , Prévalence , Poumon/physiopathologie , Ostéoporose post-ménopausique/physiopathologie , Ostéoporose post-ménopausique/ethnologie , Ostéoporose post-ménopausique/diagnostic , Ostéoporose post-ménopausique/épidémiologie , Valeur prédictive des tests , Modèles logistiques , Appréciation des risques , Densité osseuse , Modèles linéaires , Broncho-pneumopathie chronique obstructive/physiopathologie , Broncho-pneumopathie chronique obstructive/diagnostic , Broncho-pneumopathie chronique obstructive/ethnologie , Broncho-pneumopathie chronique obstructive/épidémiologie , Auto-évaluation diagnostique , Odds ratio , Peuples d'Asie de l'Est
5.
BMC Pulm Med ; 24(1): 339, 2024 Jul 12.
Article de Anglais | MEDLINE | ID: mdl-38997676

RÉSUMÉ

BACKGROUND: Chronic lung disease (CLD) is common among children with HIV (CWH) including in those taking antiretroviral therapy (ART). Azithromycin has both antimicrobial and anti-inflammatory effects and has been effective in improving lung function in a variety of lung diseases. We investigated lung function trajectories among CWH with CLD on ART enrolled in a randomized controlled trial of adjuvant azithromycin. We also investigated factors that modified the effect of azithromycin on lung function. METHODS: The study used data from a double-blinded placebo-controlled trial conducted in Malawi and Zimbabwe of 48 weeks on azithromycin (BREATHE: ClinicalTrials.gov NCT02426112) among CWH aged 6 to 19 years taking ART for at least six months who had a forced expiratory volume in one second (FEV1) z-score <-1.0. Participants had a further follow-up period of 24 weeks after intervention cessation. FEV1, forced vital capacity (FVC) and FEV1/FVC were measured at baseline, 24, 48 and 72-weeks and z-scores values calculated. Generalized estimating equations (GEE) models were used to determine the mean effect of azithromycin on lung-function z-scores at each follow-up time point. RESULTS: Overall, 347 adolescents (51% male, median age 15 years) were randomized to azithromycin or placebo. The median duration on ART was 6.2 (interquartile range: 3.8-8.6) years and 56.2% had an HIV viral load < 1000copies/ml at baseline. At baseline, the mean FEV1 z-score was - 2.0 (0.7) with 44.7% (n = 155) having an FEV1 z-score <-2, and 10.1% had microbiological evidence of azithromycin resistance. In both trial arms, FEV1 and FVC z-scores improved by 24 weeks but appeared to decline thereafter. The adjusted overall mean difference in FEV1 z-score between the azithromycin and placebo arms was 0.004 [-0.08, 0.09] suggesting no azithromycin effect and this was similar for other lung function parameters. There was no evidence of interaction between azithromycin effect and baseline age, lung function, azithromycin resistance or HIV viral load. CONCLUSION: There was no observed azithromycin effect on lung function z-scores at any time point suggesting no therapeutic effect on lung function. TRIAL REGISTRATION: ClinicalTrials.gov NCT02426112. First registered on 24/04/2015.


Sujet(s)
Azithromycine , Infections à VIH , Maladies pulmonaires , Humains , Azithromycine/usage thérapeutique , Infections à VIH/traitement médicamenteux , Infections à VIH/complications , Mâle , Adolescent , Femelle , Enfant , Méthode en double aveugle , Volume expiratoire maximal par seconde/effets des médicaments et des substances chimiques , Maladie chronique , Capacité vitale , Maladies pulmonaires/traitement médicamenteux , Maladies pulmonaires/physiopathologie , Antibactériens/usage thérapeutique , Jeune adulte , Malawi , Poumon/physiopathologie , Poumon/effets des médicaments et des substances chimiques , Zimbabwe , Tests de la fonction respiratoire , Études longitudinales
6.
Int J Chron Obstruct Pulmon Dis ; 19: 1421-1431, 2024.
Article de Anglais | MEDLINE | ID: mdl-38948906

RÉSUMÉ

Objective: To determine the association of urinary phthalate metabolites with chronic obstructive pulmonary disease (COPD), airflow obstruction, lung function and respiratory symptoms. Methods: Our study included a total of 2023 individuals aged ≥ 40 years old in the National Health and Nutrition Examination Survey (NHANES). Multivariate logistic regression was conducted to explore the correlation of eleven urinary phthalate metabolites (MCNP, MCOP, MECPP, MnBP, MCPP, MEP, MEHHP, MEHP, MiBP, MEOHP, and MBzP) with COPD, airflow obstruction and respiratory symptoms. Linear regression analyses were used to evaluate the relationship between urinary phthalate metabolites and lung function. Results: When compared to the first tertile, the third tertile of MEHHP was associated with the risk of COPD [OR: 2.779; 95% confidence interval (CI): 1.129-6.840; P = 0.026]. Stratified analysis showed that MEHHP increased the risk of COPD by 7.080 times in male participants. Both MCPP and MBzP were positively correlated with the risk of airflow obstruction. The third tertile of MBzP increased the risk of cough by 1.545 (95% CI: 1.030-2.317; P = 0.035) times. Both FEV1 and FVC were negatively associated with MEHHP, MECPP, MnBP, MEP, MiBP and MEOHP. Conclusion: Higher levels of MEHHP are associated with increased risk of COPD, and lower measures of FEV1 and FVC. MBzP is positively related to airflow obstruction and cough.


Sujet(s)
Marqueurs biologiques , Poumon , Enquêtes nutritionnelles , Acides phtaliques , Broncho-pneumopathie chronique obstructive , Humains , Broncho-pneumopathie chronique obstructive/urine , Broncho-pneumopathie chronique obstructive/physiopathologie , Broncho-pneumopathie chronique obstructive/diagnostic , Broncho-pneumopathie chronique obstructive/épidémiologie , Mâle , Études transversales , Femelle , Adulte d'âge moyen , Facteurs de risque , Poumon/physiopathologie , Volume expiratoire maximal par seconde , Acides phtaliques/urine , Adulte , Marqueurs biologiques/urine , États-Unis/épidémiologie , Capacité vitale , Sujet âgé , Analyse multifactorielle , Odds ratio , Modèles linéaires , Modèles logistiques , Toux/physiopathologie , Toux/urine , Toux/épidémiologie
7.
Int J Chron Obstruct Pulmon Dis ; 19: 1515-1529, 2024.
Article de Anglais | MEDLINE | ID: mdl-38974817

RÉSUMÉ

Purpose: The aim of this study was to evaluate the association between computed tomography (CT) quantitative pulmonary vessel morphology and lung function, disease severity, and mortality risk in patients with chronic obstructive pulmonary disease (COPD). Patients and Methods: Participants of the prospective nationwide COSYCONET cohort study with paired inspiratory-expiratory CT were included. Fully automatic software, developed in-house, segmented arterial and venous pulmonary vessels and quantified volume and tortuosity on inspiratory and expiratory scans. The association between vessel volume normalised to lung volume and tortuosity versus lung function (forced expiratory volume in 1 sec [FEV1]), air trapping (residual volume to total lung capacity ratio [RV/TLC]), transfer factor for carbon monoxide (TLCO), disease severity in terms of Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D, and mortality were analysed by linear, logistic or Cox proportional hazard regression. Results: Complete data were available from 138 patients (39% female, mean age 65 years). FEV1, RV/TLC and TLCO, all as % predicted, were significantly (p < 0.05 each) associated with expiratory vessel characteristics, predominantly venous volume and arterial tortuosity. Associations with inspiratory vessel characteristics were absent or negligible. The patterns were similar for relationships between GOLD D and mortality with vessel characteristics. Expiratory venous volume was an independent predictor of mortality, in addition to FEV1. Conclusion: By using automated software in patients with COPD, clinically relevant information on pulmonary vasculature can be extracted from expiratory CT scans (although not inspiratory scans); in particular, expiratory pulmonary venous volume predicted mortality. Trial Registration: NCT01245933.


Sujet(s)
Poumon , Valeur prédictive des tests , Artère pulmonaire , Broncho-pneumopathie chronique obstructive , Indice de gravité de la maladie , Humains , Femelle , Broncho-pneumopathie chronique obstructive/physiopathologie , Broncho-pneumopathie chronique obstructive/mortalité , Broncho-pneumopathie chronique obstructive/diagnostic , Mâle , Sujet âgé , Adulte d'âge moyen , Études prospectives , Facteurs de risque , Volume expiratoire maximal par seconde , Poumon/physiopathologie , Poumon/imagerie diagnostique , Poumon/vascularisation , Artère pulmonaire/physiopathologie , Artère pulmonaire/imagerie diagnostique , Appréciation des risques , Pronostic , Veines pulmonaires/physiopathologie , Veines pulmonaires/imagerie diagnostique , Veines pulmonaires/malformations , Angiographie par tomodensitométrie , Interprétation d'images radiographiques assistée par ordinateur , Modèles des risques proportionnels , Modèles linéaires , Tomodensitométrie multidétecteurs , Modèles logistiques , Pays-Bas
8.
Int J Chron Obstruct Pulmon Dis ; 19: 1579-1589, 2024.
Article de Anglais | MEDLINE | ID: mdl-38983577

RÉSUMÉ

Purpose: Pulmonary rehabilitation (PR) is a type of multidisciplinary care strongly recommended after severe exacerbation of chronic obstructive pulmonary disease (COPD). Recently, a national French study reported a very low rate of PR uptake (8.6%); however, important clinical data were missing. Here, we aimed to identify the main factors associated with insufficient PR uptake after hospitalisation for COPD exacerbation. Patients and Methods: This multicentre retrospective study included patients hospitalised with COPD exacerbation between 1 January 2017 and 31 December 2018, as identified by both coding and a detailed review of medical records. PR was defined as inpatient care in a specialised centre or unit within 90 days of discharge. Multivariate logistic regression was used to identify associations between PR uptake and patient characteristics, such as comorbidities, non-invasive ventilation (NIV), inhaled treatment, and forced expiratory volume in 1 second (FEV1). Results: Among the 325 patients admitted for severe COPD exacerbation, 92 (28.3%) underwent PR within 90 days of discharge. In univariate analysis, relative to those who underwent PR, patients without PR had significantly more comorbidities, were less often treated with triple bronchodilator therapy or NIV, and had a higher FEV1. In multivariate analysis, variables independently associated with the lack of PR uptake were the presence of comorbidities (adjusted odds ratio (aOR) = 1.28 [1.10-1.53], p = 0.003) and a higher FEV1 (aOR = 1.04 [1.02-1.06], p < 0.001). There was no significant correlation between PR uptake and departmental PR centre capacity (notably, some departments had no PR facilities). Conclusion: These data highlight the lack of PR in the early stages of COPD. Collaboration among all healthcare providers involved in patient management is crucial for improved PR uptake.


Pulmonary rehabilitation (PR) is multidisciplinary care strongly recommended after severe exacerbation of chronic obstructive pulmonary disease (COPD); however, referral remains very low in France. We have shown, in three French centres, that early-stage COPD and associated comorbidities are the main factors contributing to insufficient PR after hospitalisation for exacerbation. Collaboration among all healthcare providers involved in patient management is crucial to improve PR uptake in the years ahead because physical medicine and rehabilitation professionals play key roles in the promotion and early initiation of PR programs.


Sujet(s)
Évolution de la maladie , Broncho-pneumopathie chronique obstructive , Indice de gravité de la maladie , Humains , Broncho-pneumopathie chronique obstructive/rééducation et réadaptation , Broncho-pneumopathie chronique obstructive/physiopathologie , Broncho-pneumopathie chronique obstructive/diagnostic , Broncho-pneumopathie chronique obstructive/épidémiologie , Broncho-pneumopathie chronique obstructive/thérapie , Mâle , Études rétrospectives , Femelle , Sujet âgé , France/épidémiologie , Adulte d'âge moyen , Facteurs temps , Volume expiratoire maximal par seconde , Poumon/physiopathologie , Résultat thérapeutique , Facteurs de risque , Ventilation non effractive/statistiques et données numériques , Bronchodilatateurs/usage thérapeutique , Comorbidité , Sujet âgé de 80 ans ou plus , Récupération fonctionnelle
9.
BMC Public Health ; 24(1): 1791, 2024 Jul 05.
Article de Anglais | MEDLINE | ID: mdl-38970028

RÉSUMÉ

BACKGROUND: Orang Asli lifestyle and household setting may influence their health status especially respiratory system and lung functions. This cross-sectional study was carried out to investigate the status of lung functions of Orang Asli community and the associated factors. METHODS: Data collection was carried out from November 2017 until May 2018 among 211 Orang Asli respondents aged 18 years old and above, who lived in five villages in Tasik Chini, Pahang. All respondents who fulfilled the inclusion criteria were recruited in this study. Interview-guided questionnaire was administered, and spirometry test that include Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC), and Peak Expiratory Flow Rate (PEFR) was carried out. Data were analyzed using SPSS software version 23.0. In the first stage, descriptive analysis was done to describe the characteristics of the respondents. In the second stage, bivariable analysis was carried out to compare proportions. Finally, multiple logistic regression was performed to assess the effects of various independent predictors on spirometry parameters. RESULTS: The respondents' age ranged from 18 to 71 years old in which 50.2% of them were female. The majority ethnicity in Tasik Chini was Jakun tribe (94.3%). More than half of the respondents (52.1%) were current smoker, 5.2% were ex-smoker and 41.7% were non-smoker. More than half of them (62.1%) used woodstove for cooking, compared to only 37.9% used cleaner fuel like Liquefied Petroleum Gas (LPG) as a fuel for everyday cooking activity. The lung function parameters (FEV1 and FVC) were lower than the predictive value, whereas the ratio of Forced Expiratory Volume in one second and Forced Vital Capacity (FEV1/FVC) (%) and PEFR were within the predictive value. The FEV1 levels were significantly associated with age group (18-39 years old) (p = 0.002) and presence of woodstove in the house (p = 0.004). FVC levels were significantly associated with presence of woodstove in the house (p = 0.004), whereas there were no significant associations between all factors and FEV1/FVC levels. CONCLUSIONS: FEV1 levels were significantly associated with age group 18-39 years old, whereas FVC levels were significantly associated with the presence of woodstove in the house. Thus, environmental interventions such as replacing the use of woodstove with LPG, need to be carried out to prevent further worsening of respiratory health among Orang Asli who lived far from health facilities. Moreover, closer health monitoring is crucial especially among the younger and productive age group.


Sujet(s)
Spirométrie , Humains , Études transversales , Femelle , Mâle , Adulte , Adulte d'âge moyen , Malaisie/épidémiologie , Adolescent , Sujet âgé , Jeune adulte , Tests de la fonction respiratoire , Enquêtes et questionnaires , Poumon/physiologie , Capacité vitale/physiologie , Volume expiratoire maximal par seconde
10.
Sci Rep ; 14(1): 15337, 2024 07 03.
Article de Anglais | MEDLINE | ID: mdl-38961087

RÉSUMÉ

Characteristics of chronic obstructive pulmonary disease (COPD) patients with superoptimal peak inspiratory flow rates (PIFR) has not been thoroughly investigated. This study aimed to compare the characteristics between COPD patients with superoptimal PIFR and those with optimal and sub-optimal PIFR. PIFR was measured using In-Check DIAL G16 and categorized into sub-optimal (PIFR lower than that required by the patient's device), optimal, and superoptimal (peak PIFR ≥ 90 L/min). Considering COPD patients with sub-optimal PIFR as the reference group, analyses were performed to identify PIFR-related factors. Subgroup analysis was performed according to the forced expiratory volume in 1 s (FEV1) % of the predicted value (%pred). Among 444 post-bronchodilator-confirmed COPD patients from seven tertiary hospitals in South Korea, 98, 223, and 123 were classified into the sub-optimal, optimal, and superoptimal PIFR groups, respectively. The superoptimal PIFR group were younger, had an increased proportion of males, a higher body mass index, lowest number of comorbidities and less frequent exacerbation in the previous year, as well as the highest forced vital capacity %pred. The adjusted odds ratio for frequent exacerbation in the previous year was lower in the superoptimal PIFR group than in the sub-optimal PIFR group and was more pronounced in patients with an FEV1%pred of < 70%. COPD patients with superoptimal PIFR have clinical characteristics different from those patients with the sub-optimal and optimal PIFR. Having a high inspiratory flow may be a favorable trait in COPD.


Sujet(s)
Broncho-pneumopathie chronique obstructive , Humains , Broncho-pneumopathie chronique obstructive/physiopathologie , Mâle , Femelle , Sujet âgé , Adulte d'âge moyen , Volume expiratoire maximal par seconde , Inspiration/physiologie , République de Corée/épidémiologie , Capacité vitale
11.
BMC Pulm Med ; 24(1): 319, 2024 Jul 04.
Article de Anglais | MEDLINE | ID: mdl-38965493

RÉSUMÉ

BACKGROUND: Obesity is a major public health concern associated with various health problems, including respiratory impairment. Bioelectrical impedance (BIA) is used in health screening to assess body fat. However, there is no consensus in healthcare on how body fat should be assessed in relation to lung function. In this study, we aimed to investigate how BIA in relation to waist circumference contribute, using data from a large Swedish population study. METHODS: A total of 17,097 participants (aged 45-75 years) were included in the study. The relationships between fat mass, waist circumference, and lung function were analysed using weighted quantile sum regression. RESULTS: Increased fat mass was significantly associated with decreased lung function (FEV1, FVC) in both sexes. Also, the influence of trunk fat and waist circumference on FVC and FEV1 differed by sex: in males, waist circumference and trunk fat had nearly equal importance for FVC (variable weights of 0.42 and 0.41), whereas in females, trunk fat was significantly more important (variable weights 0.84 and 0.14). For FEV1, waist circumference was more important in males, while trunk fat was more significant in females (variable weights male 0.68 and 0.28 and 0.23 and 0.77 in female). CONCLUSIONS: Our results suggest that trunk fat should be considered when assessing the impact of adipose tissue on lung function and should potentially be included in the health controls.


Sujet(s)
Impédance électrique , Obésité abdominale , Tour de taille , Humains , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Suède , Facteurs sexuels , Obésité abdominale/physiopathologie , Volume expiratoire maximal par seconde , Capacité vitale , Poumon/physiopathologie , Tests de la fonction respiratoire , Études transversales
12.
BMJ Open Respir Res ; 11(1)2024 Jul 17.
Article de Anglais | MEDLINE | ID: mdl-39019624

RÉSUMÉ

OBJECTIVE: We aimed to elucidate the clinical factors associated with acute exacerbation and disease progression in young patients with chronic obstructive pulmonary disease (COPD). METHODS: This retrospective longitudinal observational study included patients with COPD aged between 20 and 50 years with post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)<0.7. Eligible patients were followed up with ≥2 spirometry examinations at 1 year interval after COPD diagnosis. The primary outcome was moderate-to-severe acute exacerbation in young patients with COPD. Secondary outcomes were early initiation of regular inhalation therapy and accelerated annual post-bronchodilator FEV1 decline. RESULTS: A total of 342 patients were followed up during a median of 64 months. In multivariable analyses, risk factors for moderate-to-severe exacerbation were history of asthma (adjusted HR (aHR)=2.999, 95% CI=[2.074-4.335]), emphysema (aHR=1.951, 95% CI=[1.331-2.960]), blood eosinophil count >300/µL (aHR=1.469, 95% CI=[1.038-2.081]) and low FEV1 (%) (aHR=0.979, 95% CI=[0.970-0.987]). A history of asthma, sputum, blood eosinophil count >300/µL, low FEV1 (%) and low diffusing capacity of the lung for carbon monoxide (DLCO) (%) were identified as clinical factors associated with the early initiation of regular inhalation therapy. The risk factors associated with worsened FEV1 decline were increasing age, female sex, history of pulmonary tuberculosis, sputum, low FEV1 (%) and low DLCO (%). CONCLUSIONS: In young COPD patients, specific high-risk features of acute exacerbation and disease progression need to be identified, including a history of previous respiratory diseases, current respiratory symptoms, blood eosinophil counts, and structural or functional pulmonary impairment.


Sujet(s)
Évolution de la maladie , Broncho-pneumopathie chronique obstructive , Humains , Broncho-pneumopathie chronique obstructive/physiopathologie , Broncho-pneumopathie chronique obstructive/diagnostic , Femelle , Mâle , Facteurs de risque , Études rétrospectives , Adulte , Adulte d'âge moyen , Volume expiratoire maximal par seconde , Études longitudinales , Capacité vitale , Jeune adulte , Asthme/physiopathologie , Asthme/diagnostic , Asthme/traitement médicamenteux , Spirométrie , Bronchodilatateurs/usage thérapeutique , Bronchodilatateurs/administration et posologie , Granulocytes éosinophiles
13.
Turk J Pediatr ; 66(3): 297-308, 2024 Jul 11.
Article de Anglais | MEDLINE | ID: mdl-39024602

RÉSUMÉ

BACKGROUND: The lung clearance index (LCI) is a sensitive lung function index that is used to detect early lung disease changes in children with cystic fibrosis (CF). This study aimed to define the predictive role of baseline LCI, along with other potential factors on the change in forced expiratory volume in one second (FEV1) during one-year follow-up in CF patients who had a percent predicted (pp) FEV1≥80. METHODS: LCI was concurrently performed on 57 CF patients who had ppFEV1 ≥80 at month zero. The ppFEV1 decline was evaluated prospectively during the one year follow up. The primary outcome of ppFEV1 decline in the study group in one year was dichotomized according to the median value for the decline in ppFEV1, which was 3.7. The LCI value predicting ppFEV1 decline at the end of one year was calculated with receiver operating characteristic curve analysis. Regression analysis was performed. Furthermore, a decision tree was constructed using classification and regression tree methods to better define the potential effect of confounders on the ppFEV1 decline. RESULTS: The LCI value for predicting ppFEV1 decline >3.7% at the end of one year was 8.2 (area under the curve: 0.80) Multivariable regression analysis showed that the absence of the F508del mutation in at least one allele, LCI >8.2 and initial FEV1 z-score were predictors of a ppFEV1 decline >3.7 (p<0.001). Factors altering ppFEV1 decline>3.7% at the end of one-year evaluated by decision trees were as follows: initial FEV1 z-score, type of CFTR mutation, LCI value and initial weight-for-age z-score. CONCLUSIONS: LCI is sensitive for predicting ppFEV1 decline in patients with ppFEV1 ≥80 along with the initial FEV1-z-score and type of CFTR mutation.


Sujet(s)
Mucoviscidose , Humains , Mucoviscidose/physiopathologie , Mucoviscidose/génétique , Femelle , Mâle , Volume expiratoire maximal par seconde , Enfant , Adolescent , Tests de la fonction respiratoire , Valeur prédictive des tests , Études prospectives , Poumon/physiopathologie
14.
Microbiome ; 12(1): 129, 2024 Jul 18.
Article de Anglais | MEDLINE | ID: mdl-39026261

RÉSUMÉ

BACKGROUND: Chronic exposure to microorganisms inside homes can impact respiratory health. Few studies have used advanced sequencing methods to examine adult respiratory outcomes, especially continuous measures. We aimed to identify metagenomic profiles in house dust related to the quantitative traits of pulmonary function and airway inflammation in adults. Microbial communities, 1264 species (389 genera), in vacuumed bedroom dust from 779 homes in a US cohort were characterized by whole metagenome shotgun sequencing. We examined two overall microbial diversity measures: richness (the number of individual microbial species) and Shannon index (reflecting both richness and relative abundance). To identify specific differentially abundant genera, we applied the Lasso estimator with high-dimensional inference methods, a novel framework for analyzing microbiome data in relation to continuous traits after accounting for all taxa examined together. RESULTS: Pulmonary function measures (forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio) were not associated with overall dust microbial diversity. However, many individual microbial genera were differentially abundant (p-value < 0.05 controlling for all other microbial taxa examined) in relation to FEV1, FVC, or FEV1/FVC. Similarly, fractional exhaled nitric oxide (FeNO), a marker of airway inflammation, was unrelated to overall microbial diversity but associated with differential abundance for many individual genera. Several genera, including Limosilactobacillus, were associated with a pulmonary function measure and FeNO, while others, including Moraxella to FEV1/FVC and Stenotrophomonas to FeNO, were associated with a single trait. CONCLUSIONS: Using state-of-the-art metagenomic sequencing, we identified specific microorganisms in indoor dust related to pulmonary function and airway inflammation. Some were previously associated with respiratory conditions; others were novel, suggesting specific environmental microbial components contribute to various respiratory outcomes. The methods used are applicable to studying microbiome in relation to other continuous outcomes. Video Abstract.


Sujet(s)
Poussière , Métagénome , Microbiote , Poussière/analyse , Humains , Femelle , Mâle , États-Unis , Microbiote/génétique , Adulte d'âge moyen , Poumon/microbiologie , Adulte , Bactéries/classification , Bactéries/génétique , Bactéries/isolement et purification , Volume expiratoire maximal par seconde , Agriculture , Tests de la fonction respiratoire , Capacité vitale , Métagénomique/méthodes
15.
Ann Afr Med ; 23(2): 194-201, 2024 Apr 01.
Article de Français, Anglais | MEDLINE | ID: mdl-39028169

RÉSUMÉ

INTRODUCTION: Years after SARS coronavirus disease 2019 (COVID-19) recovery, residual pulmonary abnormalities may still exist. This brings on the question of whether or not COVID-19 could have comparable late consequences. Structural changes in the lungs after recovery can be better visualized using computed tomography (CT) thorax. Computed Tomography Lung Parenchymal changes during hospitalization by COVID-19 and after 4 months of follow-up to correlate with the volumetric high-resolution computed tomography thorax indices, Pulmonary function tests (PFTs) indices, SpO2, and 6 min Walking Test (6MWT). MATERIALS AND METHODS: This is a Hospital based cross-sectional study, with a follow-up among 100 Patients from 2020 to 2022. Each patient's different CT parameters and HRCT volumetric indices Normal Lung (NL), Normal Lung Percentage (NL%), Whole Lung (WL) were correlated with the PFT indices (Forced expiratory volume in 1s [FEV1], forced vital capacity [FVC], FEV1/FVC), Oxygen Saturation (SpO2) and 6-Minute Walking Test (6MWT). RESULTS: The mean NL (L) and NL% during COVID were significantly lower than the mean values 4 months post-COVID. Architectural distortion, bronchiolar dilatation, interstitial thickening, and parenchymal bands were reduced considerably after 4 months post-COVID, compared to during COVID. PFTs results, such as PFT indices, were not significantly different after 4 months post-COVID, compared to during COVID. SpO2 (%) and 6 MWT (m) were significantly increased. During COVID and post-COVID, the values of NL (L) and NL (%) had a significant positive correlation with PFT indices, SpO2, and 6MWT (m). CONCLUSION: Hence, the different CT indices (NL and NL%) can be used as a surrogate for functional recovery of COVID patients since it correlates with the PFT indices (FEV1 and FEV1/FVC), SpO2, and 6MWT post-COVID.


Résumé Introduction:Des années après la guérison du SRAS Covid-19, des anomalies pulmonaires résiduelles peuvent encore exister. Cela amène à se demander si le Covid-19 pourrait ou non avoir des conséquences tardives comparables. Les changements structurels dans les poumons après la récupération peuvent être mieux visualisés à l'aide de CT-Thorax. Étudier les changements CT post-Covid pendant l'hospitalisation et après quatre mois de suivi de l'infection, et corréler les indices volumétriques du thorax HRCT avec les indices des tests de la fonction pulmonaire (PFT), la SpO2 et le test de marche de 6 min (6MWT).Matériels et méthodes:Il s'agit d'une étude transversale en milieu hospitalier, avec un suivi de 100 patients de 2020 à 2022. Les différents paramètres CT et indices volumétriques HRCT de chaque patient Poumon normal (NL), Pourcentage pulmonaire normal (NL%), Les poumons entiers (WL) étaient corrélés avec les indices PFT (volume expiratoire forcé en 1 s [FEV1], capacité vitale forcée [FVC], FEV1/FVC), saturation en oxygène (SpO2) et test de marche de 6 minutes (6MWT).Résultats:Les moyennes NL (L) et NL% pendant le Covid étaient significativement inférieures aux valeurs moyennes 4 mois post-covid. La distorsion architecturale, la dilatation bronchiolaire, l'épaississement interstitiel et les bandes parenchymateuses ont été considérablement réduits après 4 mois post-covid, par rapport à pendant Covid. Les résultats des tests de la fonction pulmonaire, tels que les indices PFT, n'étaient pas significativement différents après 4 mois post-covid, par rapport à pendant Covid. SpO2 (%) et 6 MWT (m) ont été significativement augmentés. Pendant Covid et post-covid, les valeurs de NL (L) et NL (%) avaient une corrélation positive significative avec les indices PFT, SpO2 et 6 MWT (m).Conclusion:Ainsi, les différents indices CT (NL, NL %) peuvent être utilisés comme substitut de la récupération fonctionnelle des patients Covid car ils sont corrélés aux indices PFT (FEV1, FEV1/FVC), SpO2, 6-MWT post-covid.


Sujet(s)
COVID-19 , Poumon , Tests de la fonction respiratoire , SARS-CoV-2 , Tomodensitométrie , Humains , COVID-19/imagerie diagnostique , COVID-19/physiopathologie , Mâle , Femelle , Tomodensitométrie/méthodes , Études transversales , Adulte d'âge moyen , Poumon/imagerie diagnostique , Poumon/physiopathologie , Adulte , Capacité vitale/physiologie , Volume expiratoire maximal par seconde/physiologie , Test de marche , Sujet âgé
16.
Eur J Sport Sci ; 24(7): 964-974, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38956787

RÉSUMÉ

The prolonged consequences of SARS-CoV-2 on young elite athletes recovering from primary and reinfection are unclear. This study aimed to assess inspiratory/expiratory muscle strength and respiratory function at the time of spontaneous recovery at 3, 6, and 9 months after SARS-CoV-2 primary and reinfection in elite athletes. The study enrolled 25 elite male judoists, including 11 primary infection cases, five reinfection cases, and nine controls from the Türkiye Olympic Preparation Center. Inspiratory/expiratory muscle strength and respiratory function were measured, including maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC, and peak expiratory flow (PEF) before and up to 9 months after SARS-CoV-2 infection in the early pre-competition preparation phases. The most common symptoms reported by reinfection cases were fatigue (80%), dyspnea (60%), and muscle/joint pain (60%), while primary infection cases reported fatigue (73%), muscle/joint pain (45%), and headache (45%). MIP decreased by -14% and MEP decreased by -13% following the SARS-CoV-2 infection in reinfection cases. Likewise, FEV1 and FVC decreased by -5% and -8%, respectively; consequently, FEV1/FVC increased by 3%. Inspiratory/expiratory muscle strength and respiratory function improved rapidly after 9 months of SARS-CoV-2 infection in primary cases, whereas dysfunction persisted in reinfection cases. PEF was unaffected throughout the 9-month follow-up period. Reinfection may lead to further alterations in respiratory system relative to the primary infection, with a suspected restrictive pattern that remains dysfunctional in the third month; however, it improves significantly during a 9-month follow-up period.


Sujet(s)
COVID-19 , Force musculaire , Qualité de vie , Humains , Mâle , Études prospectives , Études de suivi , Force musculaire/physiologie , Jeune adulte , Muscles respiratoires/physiologie , Muscles respiratoires/physiopathologie , Athlètes , Performance sportive/physiologie , Réinfection , SARS-CoV-2 , Tests de la fonction respiratoire , Fatigue/physiopathologie , Dyspnée/physiopathologie , Adolescent , Capacité vitale , Céphalée , Volume expiratoire maximal par seconde
17.
BMC Pulm Med ; 24(1): 345, 2024 Jul 16.
Article de Anglais | MEDLINE | ID: mdl-39014325

RÉSUMÉ

BACKGROUND: In advanced chronic obstructive pulmonary disease (COPD), hypercapnia may occur due to severe bronchial obstruction with lung hyperinflation. Non-invasive ventilation (NIV) provides the standard of care intended to achieve physiological PCO2 levels, thereby reducing overall mortality. The present study aimed to evaluate pulmonary function parameters derived from spirometry (forced vital capacity [FVC], forced expiratory volume in 1 s [FEV1]), body plethysmography (residual volume [RV], total lung capacity [TLC]), and lung diffusion capacity for carbon monoxide (single-breath method [DCO-SB], alveolar-volume corrected values [DCO-VA]) as predictors of chronic hypercapnia in patients with advanced COPD. METHODS: This monocentric, retrospective observational study included 423 COPD patients. Receiver operating characteristic (ROC) curve analysis and cross-validation were used to assess lung function parameters' diagnostic accuracy for predicting chronic hypercapnia, with the resulting performance expressed as area under the ROC curve (AUROC). We performed univariable and multivariable binary logistic regression analysis to determine if these parameters were independently associated with chronic hypercapnia, with probabilities reported as odds ratios [OR] with 95% confidence intervals [95%CI]. RESULTS: FVC% (AUROC 0.77 [95%CI 0.72-0.81], P < 0.01) and FEV1% (AURIC 0.75 [95%CI 0.70-0.79], P < 0.01) exhibited reasonable accuracy in the prediction of chronic hypercapnia, whereas lung diffusion capacity performed poorly (AUROC 0.64 [95%CI 0.58-0.71] for DCO-SB%, P < 0.01). FVC% (OR 0.95 [95%CI 0.93-0.97], P < 0.01) and FEV1% (OR 0.97 [95%CI 0.94-0.99], P = 0.029) were the only parameters associated independently with chronic hypercapnia in logistic regression analysis. FVC and FEV1 thresholds that best separated hypercapnic from normocapnic subjects reached 56% and 33% of predicted values. CONCLUSIONS: Routinely collected pulmonary function parameters, particularly FVC% and FEV1%, may predict chronic hypercapnia during COPD progression.


Sujet(s)
Hypercapnie , Broncho-pneumopathie chronique obstructive , Courbe ROC , Spirométrie , Humains , Hypercapnie/physiopathologie , Broncho-pneumopathie chronique obstructive/physiopathologie , Broncho-pneumopathie chronique obstructive/complications , Mâle , Femelle , Sujet âgé , Études rétrospectives , Adulte d'âge moyen , Volume expiratoire maximal par seconde , Capacité vitale , Poumon/physiopathologie , Modèles logistiques , Capacité pulmonaire totale , Tests de la fonction respiratoire
18.
F1000Res ; 13: 296, 2024.
Article de Anglais | MEDLINE | ID: mdl-38835937

RÉSUMÉ

Background: Pulmonary involvement is a major cause of internal organ complication and the leading cause of death in patients with systemic sclerosis (SSc). This study aimed to demonstrate the characteristics of pulmonary function (PF) in Thai patients with SSc and the association between PF and body mass index (BMI) and anti-topoisomerase (anti-Scl70). Methods: All patients diagnosed with SSc in our tertiary care teaching hospital database between 2016 and 2021 were reviewed and analyzed. Results: Of 211 SSc patients, 128 patients who underwent the PF test were enrolled; 102 (79.7%) were female. The mean age was 54 years. The median BMI for all patients was 21.7 kg/m 2. Regarding anti-Scl70, 10.9% of patients were positive, 7.8% were negative, and the status was unreported for 81.3%. The mean (SD) forced expiratory volume in one second (FEV1) forced vital capacity (FVC) ratio was 0.8 (0.1). The mean (SD) % predicted values of FEV1, FVC, and diffusing capacity of the lungs for carbon monoxide (DLCO) were 76.3 (16.3), 69.1 (15.8), and 75.5 (22.8), respectively. A restrictive spirometry pattern (RSP) was found in 78.8% of the patients. DLCO had a moderate positive linear correlation with FVC (r=0.50, p <0.001) and a moderate negative linear correlation with BMI (r=-0.36, p <0.001). However, there was no correlation between FVC and BMI. There was no statistical difference in demographic data or the presence of anti-Scl70 among patients with or without RSP. Conclusions: RSP is common among Thai patients with SSc. However, the power of using demographic data and the presence of anti-Scl70 to determine the probability of pulmonary involvement remains limited.


Sujet(s)
Poumon , Sclérodermie systémique , Humains , Femelle , Sclérodermie systémique/physiopathologie , Sclérodermie systémique/complications , Mâle , Adulte d'âge moyen , Études rétrospectives , Thaïlande/épidémiologie , Poumon/physiopathologie , Tests de la fonction respiratoire , Indice de masse corporelle , Adulte , Capacité vitale , Sujet âgé , Volume expiratoire maximal par seconde , Peuples d'Asie du Sud-Est
19.
Ther Adv Respir Dis ; 18: 17534666241254212, 2024.
Article de Anglais | MEDLINE | ID: mdl-38841799

RÉSUMÉ

BACKGROUND: The relationships between spirometric assessment of lung function and symptoms (including exacerbations) in patients with asthma and/or chronic obstructive pulmonary disease (COPD) in a real-life setting are uncertain. OBJECTIVES: To assess the relationships between baseline post-bronchodilator (post-BD) spirometry measures of lung function and symptoms and exacerbations in patients with a physician-assigned diagnosis of asthma and/or COPD. DESIGN: The NOVEL observational longiTudinal studY (NOVELTY) is a global, prospective, 3-year observational study. METHODS: Logistic regression analysis was used to evaluate relationships. Spirometry measures were assessed as percent predicted (%pred). Symptoms were assessed at baseline, and exacerbations were assessed at baseline and Year 1. RESULTS: A total of 11,181 patients in NOVELTY had spirometry data (asthma, n = 5903; COPD, n = 3881; asthma + COPD, n = 1397). A 10% lower post-BD %pred forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) - adjusted for age and sex - were significantly associated with dyspnea (modified Medical Research Council ⩾ grade 2), frequent breathlessness [St George's Respiratory Questionnaire (SGRQ)], frequent wheeze attacks (SGRQ), nocturnal awakening (Respiratory Symptoms Questionnaire; ⩾1 night/week), and frequent productive cough (SGRQ). Lower post-BD %pred FEV1 and, to a lesser extent, lower post-BD %pred FVC were significantly associated with ⩾1 physician-reported exacerbation at baseline or Year 1. This association was stronger in patients with COPD than in those with asthma. CONCLUSION: In a real-life setting, reduced lung function is consistently associated with symptoms in patients with asthma, COPD, or asthma + COPD. The relationship with exacerbations is stronger in COPD only than in asthma. TRAIL REGISTRATION: clinicaltrials.gov identifier: NCT02760329 (www.clinicaltrials.gov).


Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a study performed in a real-life setting: the NOVELTY studyBackground: Asthma and chronic obstructive pulmonary disease (COPD) have many symptoms in common. To confirm diagnosis, doctors use spirometry, a test to measure the amount of air that can be breathed out from the lungs and how fast it can be blown out. The relationship between these measurements and symptoms in asthma and COPD is not well understood.Objectives: The aim of this research is to describe the characteristics, treatment, and impact of asthma and/or COPD in patients who are receiving their usual medical care.Methods: NOVELTY is a large study of around 12,000 patients across 19 countries. This analysis of NOVELTY looked at the relationships between two spirometry measurements and the symptoms of asthma and/or COPD experienced by patients. The spirometry measurements were: - forced expiratory volume in 1 second (FEV1) ­ the amount of air that can be blown out of the lungs in 1 second- forced vital capacity (FVC) ­ the amount of air that can be forcibly breathed out from the lungs after taking the deepest breath possibleResults: The lower the FEV1 and FVC, the more common the symptoms of breathlessness, wheeze attacks, night-time awakening, and coughing up of phlegm or mucus. These relationships were similar for FEV1 and FVC. Lower FEV1 was more strongly associated with worse symptoms in COPD than in asthma.Conclusion: These findings help to improve our understanding of the relationships between spirometry measures and symptoms in patients with asthma and/or COPD.


Sujet(s)
Asthme , Poumon , Broncho-pneumopathie chronique obstructive , Spirométrie , Humains , Mâle , Femelle , Broncho-pneumopathie chronique obstructive/physiopathologie , Broncho-pneumopathie chronique obstructive/diagnostic , Adulte d'âge moyen , Asthme/physiopathologie , Asthme/diagnostic , Études longitudinales , Sujet âgé , Études prospectives , Volume expiratoire maximal par seconde , Poumon/physiopathologie , Capacité vitale , Adulte , Évolution de la maladie , Bronchodilatateurs/usage thérapeutique , Enquêtes et questionnaires , Modèles logistiques , Facteurs temps
20.
RMD Open ; 10(2)2024 Jun 17.
Article de Anglais | MEDLINE | ID: mdl-38886003

RÉSUMÉ

OBJECTIVE: To compare longitudinal changes in spirometric measures between patients with rheumatoid arthritis (RA) and non-RA comparators. METHODS: We analysed longitudinal data from two prospective cohorts: the UK Biobank and COPDGene. Spirometry was conducted at baseline and a second visit after 5-7 years. RA was identified based on self-report and disease-modifying antirheumatic drug use; non-RA comparators reported neither. The primary outcomes were annual changes in the per cent-predicted forced expiratory volume in 1 s (FEV1%) and per cent predicted forced vital capacity (FVC%). Statistical comparisons were performed using multivariable linear regression. The analysis was stratified based on baseline smoking status and the presence of obstructive pattern (FEV1/FVC <0.7). RESULTS: Among participants who underwent baseline and follow-up spirometry, we identified 233 patients with RA and 37 735 non-RA comparators. Among never-smoking participants without an obstructive pattern, RA was significantly associated with more FEV1% decline (ß=-0.49, p=0.04). However, in ever smokers with ≥10 pack-years, those with RA exhibited significantly less FEV1% decline than non-RA comparators (ß=0.50, p=0.02). This difference was more pronounced among those with an obstructive pattern at baseline (ß=1.12, p=0.01). Results were similar for FEV1/FVC decline. No difference was observed in the annual FVC% change in RA versus non-RA. CONCLUSIONS: Smokers with RA, especially those with baseline obstructive spirometric patterns, experienced lower FEV1% and FEV1/FVC decline than non-RA comparators. Conversely, never smokers with RA had more FEV1% decline than non-RA comparators. Future studies should investigate potential treatments and the pathogenesis of obstructive lung diseases in smokers with RA.


Sujet(s)
Polyarthrite rhumatoïde , Fumer , Spirométrie , Humains , Polyarthrite rhumatoïde/diagnostic , Polyarthrite rhumatoïde/physiopathologie , Mâle , Femelle , Adulte d'âge moyen , Études longitudinales , Études prospectives , Fumer/effets indésirables , Fumer/épidémiologie , Sujet âgé , Volume expiratoire maximal par seconde , Capacité vitale , Broncho-pneumopathie chronique obstructive/physiopathologie , Broncho-pneumopathie chronique obstructive/épidémiologie , Broncho-pneumopathie chronique obstructive/diagnostic , Broncho-pneumopathie chronique obstructive/étiologie , Adulte , Royaume-Uni/épidémiologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...